232 related articles for article (PubMed ID: 26870991)
41. Cucurbitacin I inhibits tumorigenic ability and enhances radiochemosensitivity in nonsmall cell lung cancer-derived CD133-positive cells.
Hsu HS; Huang PI; Chang YL; Tzao C; Chen YW; Shih HC; Hung SC; Chen YC; Tseng LM; Chiou SH
Cancer; 2011 Jul; 117(13):2970-85. PubMed ID: 21225866
[TBL] [Abstract][Full Text] [Related]
42. Acquisition of cancer stem cell-like properties in non-small cell lung cancer with acquired resistance to afatinib.
Hashida S; Yamamoto H; Shien K; Miyoshi Y; Ohtsuka T; Suzawa K; Watanabe M; Maki Y; Soh J; Asano H; Tsukuda K; Miyoshi S; Toyooka S
Cancer Sci; 2015 Oct; 106(10):1377-84. PubMed ID: 26202045
[TBL] [Abstract][Full Text] [Related]
43. Signal transducer and activator of transcription 3 as molecular therapy for non-small-cell lung cancer.
Wang CY; Chao TT; Tai WT; Chang FY; Su WP; Chen YL; Chen PT; Weng CY; Yuan A; Shiau CW; Yu CJ; Chen KF
J Thorac Oncol; 2014 Apr; 9(4):488-96. PubMed ID: 24736071
[TBL] [Abstract][Full Text] [Related]
44. Key role of MEK/ERK pathway in sustaining tumorigenicity and in vitro radioresistance of embryonal rhabdomyosarcoma stem-like cell population.
Ciccarelli C; Vulcano F; Milazzo L; Gravina GL; Marampon F; Macioce G; Giampaolo A; Tombolini V; Di Paolo V; Hassan HJ; Zani BM
Mol Cancer; 2016 Feb; 15():16. PubMed ID: 26897742
[TBL] [Abstract][Full Text] [Related]
45. A novel anticancer agent SNG1153 inhibits growth of lung cancer stem/progenitor cells.
Liu S; Guo Y; Wang J; Zhu H; Han Y; Jin M; Wang J; Zhou C; Ma J; Lin Q; Wang Z; Meng K; Fu X
Oncotarget; 2016 Jul; 7(29):45158-45170. PubMed ID: 27281614
[TBL] [Abstract][Full Text] [Related]
46. Epigenetic therapy potential of suberoylanilide hydroxamic acid on invasive human non-small cell lung cancer cells.
Zhang S; Wu K; Feng J; Wu Z; Deng Q; Guo C; Xia B; Zhang J; Huang H; Zhu L; Zhang K; Shen B; Chen X; Ma S
Oncotarget; 2016 Oct; 7(42):68768-68780. PubMed ID: 27634890
[TBL] [Abstract][Full Text] [Related]
47. Physalin A exerts anti-tumor activity in non-small cell lung cancer cell lines by suppressing JAK/STAT3 signaling.
Zhu F; Dai C; Fu Y; Loo JF; Xia D; Gao SP; Ma Z; Chen Z
Oncotarget; 2016 Feb; 7(8):9462-76. PubMed ID: 26843613
[TBL] [Abstract][Full Text] [Related]
48. Epigenetic priming of non-small cell lung cancer cell lines to the antiproliferative and differentiating effects of all-trans retinoic acid.
Greve G; Schiffmann I; Lübbert M
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2171-80. PubMed ID: 26008188
[TBL] [Abstract][Full Text] [Related]
49. Enhancement of tumor initiation and expression of KCNMA1, MORF4L2 and ASPM genes in the adenocarcinoma of lung xenograft after vorinostat treatment.
Kuo WY; Wu CY; Hwu L; Lee JS; Tsai CH; Lin KP; Wang HE; Chou TY; Tsai CM; Gelovani J; Liu RS
Oncotarget; 2015 Apr; 6(11):8663-75. PubMed ID: 25796627
[TBL] [Abstract][Full Text] [Related]
50. Pifithrin-μ is efficacious against non-small cell lung cancer via inhibition of heat shock protein 70.
Zhou Y; Ma J; Zhang J; He L; Gong J; Long C
Oncol Rep; 2017 Jan; 37(1):313-322. PubMed ID: 28004121
[TBL] [Abstract][Full Text] [Related]
51. Selective inhibition of fatty acid synthase for lung cancer treatment.
Orita H; Coulter J; Lemmon C; Tully E; Vadlamudi A; Medghalchi SM; Kuhajda FP; Gabrielson E
Clin Cancer Res; 2007 Dec; 13(23):7139-45. PubMed ID: 18056164
[TBL] [Abstract][Full Text] [Related]
52. Expansion of cancer stem cell pool initiates lung cancer recurrence before angiogenesis.
Li L; Li JC; Yang H; Zhang X; Liu LL; Li Y; Zeng TT; Zhu YH; Li XD; Li Y; Xie D; Fu L; Guan XY
Proc Natl Acad Sci U S A; 2018 Sep; 115(38):E8948-E8957. PubMed ID: 30158168
[TBL] [Abstract][Full Text] [Related]
53. Inhibition of non-small cell lung cancer (NSCLC) growth by a novel small molecular inhibitor of EGFR.
Li J; Deng H; Hu M; Fang Y; Vaughn A; Cai X; Xu L; Wan W; Li Z; Chen S; Yang X; Wu S; Xiao J
Oncotarget; 2015 Mar; 6(9):6749-61. PubMed ID: 25730907
[TBL] [Abstract][Full Text] [Related]
54. Wnt signaling regulates the stemness of lung cancer stem cells and its inhibitors exert anticancer effect on lung cancer SPC-A1 cells.
Zhang X; Lou Y; Wang H; Zheng X; Dong Q; Sun J; Han B
Med Oncol; 2015 Apr; 32(4):95. PubMed ID: 25731617
[TBL] [Abstract][Full Text] [Related]
55. ER2, a novel human anti-EGFR monoclonal antibody inhibit tumor activity in non-small cell lung cancer models.
Kang HN; Kim SH; Yun MR; Kim HR; Lim SM; Kim MS; Hong KW; Kim SM; Kim H; Pyo KH; Park HJ; Han JY; Youn HA; Chang KH; Cho BC
Lung Cancer; 2016 May; 95():57-64. PubMed ID: 27040853
[TBL] [Abstract][Full Text] [Related]
56. Effect of NELL1 on lung cancer stem‑like cell differentiation.
Zhai Y; Wei R; Sha S; Lin C; Wang H; Jiang X; Liu G
Oncol Rep; 2019 Mar; 41(3):1817-1826. PubMed ID: 30628703
[TBL] [Abstract][Full Text] [Related]
57. BBI608 inhibits cancer stemness and reverses cisplatin resistance in NSCLC.
MacDonagh L; Gray SG; Breen E; Cuffe S; Finn SP; O'Byrne KJ; Barr MP
Cancer Lett; 2018 Aug; 428():117-126. PubMed ID: 29653268
[TBL] [Abstract][Full Text] [Related]
58. Kinomic profiling of tumour xenografts derived from patients with non-small cell lung cancer confirms their fidelity and reveals potentially actionable pathways.
Tabbò F; Guerrera F; van den Berg A; Gaudiano M; Maletta F; Bessone L; Nottegar A; Costardi L; de Wijn R; Ruijtenbeek R; Delsedime L; Sapino A; Ruffini E; Hilhorst R; Inghirami G
Eur J Cancer; 2021 Feb; 144():17-30. PubMed ID: 33316635
[TBL] [Abstract][Full Text] [Related]
59. Modulation of macrophage polarization and lung cancer cell stemness by MUC1 and development of a related small-molecule inhibitor pterostilbene.
Huang WC; Chan ML; Chen MJ; Tsai TH; Chen YJ
Oncotarget; 2016 Jun; 7(26):39363-39375. PubMed ID: 27276704
[TBL] [Abstract][Full Text] [Related]
60. FGF1 and IGF1-conditioned 3D culture system promoted the amplification and cancer stemness of lung cancer cells.
Liu P; Zhang R; Yu W; Ye Y; Cheng Y; Han L; Dong L; Chen Y; Wei X; Yu J
Biomaterials; 2017 Dec; 149():63-76. PubMed ID: 29017078
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
